Figure 4 | Scientific Reports

Figure 4

From: Performance and consistency of a fluorescence-based high-throughput screening assay for use in Babesia drug screening in mice

Figure 4

Changes in white blood cell (WBC) values in uninfected and treated B. microti-infected mice. (a) Mice treated with diminazene aceturate (DA) (25 mg kg−1); (b) mice treated with allicin (100 mg kg−1), pyronaridine tetraphosphate (PYR) (125 mg kg−1), and combination therapy of DA (10 mg kg−1) and PYR (85 mg kg−1). Each value represents the mean ± standard deviation of 5 mice per experimental group. Asterisks indicate a significant difference (P < 0.05) between treated or infected mice and uninfected mice.

Back to article page